RVXCF News and Press, Resverlogix Corp From 03/07/22

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmo...

On Sat, Dec 18 th at 5pm ET broadcast on FOX Business News – BTV-Business Television visits up-and-coming innovative investment opportunities. Discover Companies to Invest In – Watch their TV feature! Azincourt Energy (OTC...

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, is in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2 COVID-19 clinical studies within ...

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) reported that its Apabetalone drug met its primary endpoint in a pulmonary arterial hypertension or 'PAH' investigator led pilot study. Resverlogix, a world leader in epigenetics,...

Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal ...

The following healthcare companies have announced actions related to the COVID-19 outbreak: More news on: Covetrus, Inc., Parallax Health Sciences, Inc., Masimo Corporation, Healthcare stocks news, Stocks on the move, Read more ...

In a recent interview (only visible to PRO+ subscribers ), I was asked about obvious shorts. This inspired me to explore the topic further. My search led me to an obscure pack of stocks, some of which I happened to stumble across before. My first thought about obvious shorts is that they ar...

The FDA has granted Breakthrough Therapy status to Resverlogix's ( OTCPK:RVXCF +14.8% ) apabetalone (RVX-208), combined with standard-of-care treatment, including high-intensity statins, for the secondary prevention of major adverse cardiac events in patients with type 2 diabetes and rec...

Resverlogix is a few days away from releasing topline results from their phase 3 clinical trial, BETonMACE, a trial that aims at showing that Apabetalone (RVX208), a BET bromodomain inhibitor, reduces the risk of heart attacks, stroke and cardiac death in a high-risk population of diabetes pat...